COCP
Income statement / Annual
Last year (2024), Cocrystal Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Cocrystal Pharma, Inc.'s net income was -$17.50 M.
See Cocrystal Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.01 M |
$6.56 M |
$0.00 |
$0.00 |
$0.00 |
$78,000.00 |
| Cost of Revenue |
$0.00
|
$15,169.00
|
$241,600.00
|
$239,500.00
|
$238,900.00
|
$4,004.00
|
$50,000.00
|
$101,000.00
|
$201,000.00
|
$192,000.00
|
| Gross Profit |
$0.00
|
-$15.17 M
|
-$241,600.00
|
-$239,500.00
|
$1.78 M
|
$6.56 M
|
-$50,000.00
|
-$101,000.00
|
-$201,000.00
|
-$114,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.88
|
1
|
0
|
0
|
0
|
-1.46
|
| Research and Development Expenses |
$12.54 M
|
$15.17 M
|
$12.39 M
|
$8.79 M
|
$6.31 M
|
$4.00 M
|
$58.57 M
|
$5.82 M
|
$101.68 M
|
$47.26 M
|
| General & Administrative Expenses |
$5.34 M
|
$5.99 M
|
$5.75 M
|
$5.43 M
|
$5.29 M
|
$4.86 M
|
$4.35 M
|
$2.44 M
|
$4.14 M
|
$6.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.34 M
|
$5.99 M
|
$5.75 M
|
$5.43 M
|
$5.29 M
|
$4.86 M
|
$4.35 M
|
$2.44 M
|
$4.14 M
|
$6.77 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$131,000.00
|
-$1,000.00
|
-$1.69 M
|
| Operating Expenses |
$17.88 M
|
$22.55 M
|
$18.14 M
|
$14.22 M
|
$11.60 M
|
$8.87 M
|
$62.92 M
|
$8.26 M
|
$105.82 M
|
$54.03 M
|
| Cost And Expenses |
$17.88 M
|
$21.16 M
|
$18.14 M
|
$14.22 M
|
$11.60 M
|
$8.87 M
|
$62.92 M
|
$8.26 M
|
$105.82 M
|
$54.03 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.00
|
$4.00
|
$8.00
|
$19.00
|
$0.00
|
$0.00
|
$126,000.00
|
$180,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2,000.00
|
$4,000.00
|
$8,000.00
|
$19,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
-$1.39 M
|
$388,000.00
|
$382,000.00
|
$336,000.00
|
$254,000.00
|
$50,000.00
|
$101,000.00
|
$201,000.00
|
$192,000.00
|
| EBITDA |
-$17.88 M |
-$19.37 M |
-$38.45 M |
-$13.80 M |
-$9.30 M |
-$47.90 M |
-$62.52 M |
-$7.39 M |
-$105.62 M |
-$53.76 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-4.62
|
-7.3
|
0
|
0
|
0
|
-689.18
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-4.76
|
-7.37
|
0
|
0
|
0
|
-691.64
|
| Total Other Income/Expenses Net |
$374,000.00
|
$575,000.00
|
-$8,000.00
|
$36,000.00
|
-$62,000.00
|
$237,000.00
|
$294,000.00
|
$769,000.00
|
$1.55 M
|
-$11.42 M
|
| Income Before Tax |
-$17.50 M
|
-$17.98 M
|
-$38.84 M
|
-$14.19 M
|
-$9.65 M
|
-$48.17 M
|
-$62.63 M
|
-$7.49 M
|
-$104.27 M
|
-$65.37 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-4.79
|
-7.34
|
0
|
0
|
0
|
-838.08
|
| Income Tax Expense |
$0.00
|
$0.00
|
$8,000.00
|
$4,000.00
|
$8,000.00
|
$19,000.00
|
-$13.58 M
|
-$6.88 M
|
-$29.39 M
|
-$15.25 M
|
| Net Income |
-$17.50 M
|
-$17.98 M
|
-$38.85 M
|
-$14.19 M
|
-$9.66 M
|
-$48.19 M
|
-$49.05 M
|
-$613,000.00
|
-$74.87 M
|
-$50.12 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-4.79
|
-7.34
|
0
|
0
|
0
|
-642.59
|
| EPS |
-1.72 |
-0.0019 |
-4.77 |
-0.16 |
-0.17 |
-1.51 |
-21.01 |
-0.3 |
-38.17 |
-28.6 |
| EPS Diluted |
-1.72 |
-0.0019 |
-4.77 |
-0.16 |
-0.17 |
-1.51 |
-21.01 |
-0.3 |
-38.14 |
-28.6 |
| Weighted Average Shares Out |
$10.17 M
|
$9.65 M
|
$8.14 M
|
$88.37 M
|
$55.22 M
|
$31.86 M
|
$2.33 M
|
$2.01 M
|
$1.96 M
|
$1.75 M
|
| Weighted Average Shares Out Diluted |
$10.17 M
|
$9.65 M
|
$8.14 M
|
$88.37 M
|
$55.22 M
|
$31.86 M
|
$2.33 M
|
$2.01 M
|
$1.96 M
|
$1.75 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
